Therapeutic impact of vildagliptin vs. gliclazide on insulin resistance and advanced glycated end product levels in newly diagnosed Egyptian diabetics: a randomized controlled trial
Vildagliptin showed a promising effect on improving type 2 diabetes mellitus-related complications by reducing advanced glycated end-product levels and insulin resistance. Additionally, vildagliptin reveals a favorable impact on weight reduction and glycated hemoglobin values.
Authors
- Toka Elemary
- Mina Nicola (ORCID: https://orcid.org/0000-0002-5183-3083)
- Dalia Zaafar (ORCID: https://orcid.org/0000-0002-7201-3658)
- Mohamed E. A. Abdelrahim (ORCID: https://orcid.org/0000-0003-2209-2674)
Institutions
- Beni-Suef University (EG)
- Modern University for Information and Technology (EG)
Publication Details
- Journal
- European Journal of Clinical Pharmacology
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1007/s00228-025-03894-8
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29